TNDM - Tandem Diabetes Care, Inc.
| Previous Close | 19.64 |
| Open | 19.30 |
| Bid | 19.70 x 1000 |
| Ask | 19.72 x 800 |
| Day's Range | 19.21 - 20.20 |
| 52 Week Range | 2.14 - 20.71 |
| Volume | 1,111,466 |
| Avg. Volume | 2,229,010 |
| Market Cap | 985.837M |
| Beta | -0.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.74 |
| Earnings Date | Jul 25, 2018 - Jul 30, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.07 |
- Zacks•5 days ago
Options Traders Expect Huge Moves in Tandem Diabetes Care (TNDM) Stock
Investors in Tandem Diabetes Care (TNDM) need to pay close attention to the stock based on moves in the options market lately.
- Investopedia•6 days ago
Artificial Pancreas Lifts Tandem Diabetes
One of the stocks we analyzed in Tuesday's Daily Market Commentary webinar was Tandem Diabetes Care Inc. ( TNDM), a medical instruments stock that after dropping from a high of $302.50 in early 2014 to a low of $2.14 in early 2018 has suddenly rebounded more than 700% during the past four months. TNDM is flying high on the hope the company is going to successfully bring its closed-loop, artificial pancreas system to market before its rivals Medtronic PLC ( MDT) and Insulet Corp. ( PODD) introduce theirs. Should it be successful, TNDM could lock up market dominance in the diabetes market for years to come.
- GlobeNewswire•7 days ago
Report: Developing Opportunities within ConocoPhillips, Teleflex, Enterprise Products Partners, Tandem Diabetes Care, J.B. Hunt Transport Services, and Ascena Retail Group — Future Expectations, Projections Moving into 2018
NEW YORK, June 12, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ConocoPhillips, ...
- ACCESSWIRE•11 days ago
Free Daily Technical Summary Reports on Tandem Diabetes Care and Three Other Medical Supplies Stocks
This morning, WallStEquities.com revisits the Medical Instruments and Supplies Manufacturing industry, which primarily researches, develops, and produces nonelectronic medical, surgical, dental, and veterinary instruments and apparatus. Under evaluation this morning are these four stocks: OraSure Technologies Inc. (NASDAQ: OSUR), ResMed Inc. (NYSE: RMD), Tandem Diabetes Care Inc. (NASDAQ: TNDM), and The Cooper Cos. Inc. (NYSE: COO). On Thursday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 507,436 shares.
- PR Newswire•18 days ago
Faruqi & Faruqi, LLP is Investigating Tandem Diabetes Care, Inc. (TNDM) on Behalf of its Shareholders
NEW YORK , June 1, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities law violations at Tandem Diabetes Care, Inc. ("Tandem" ...
- Motley Fool•22 days ago
3 Innovative Medical Technology Companies Shaking Up the Diabetes Market
These companies are helping diabetes patients better monitor and control their disease.
- Motley Fool•25 days ago
Five Top MedTech Stocks in Diabetes
Medical devices companies are revolutionizing how patients control their diabetes.
- Market Realist•28 days ago
Tandem Diabetes Care Stock Rose 44% Last Week
Tandem Diabetes Care (TNDM) witnessed a 44% rise between May 11 and May 18. On May 18, Tandem Diabetes Care stock closed at $12.83, a 500% increase from its 52-week low of $2.14 on February 9 and a 9.8% hike from the previous day’s close of $0.62.
- Motley Fool•last month
3 Healthcare Stocks That Soared This Week: Are They Buys?
Can these sizzling-hot healthcare stocks keep the momentum going?
- ACCESSWIRE•last month
Today’s Research Reports on Stocks to Watch: Tandem Diabetes Care and Galectin Therapeutics
NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Tandem shares saw an increase in their share price after an analyst at Piper Jaffray upped his price target to $13 from $8. Shares of Galectin Therapeutics also saw a rise after the company announced its plans to begin a Phase 3 clinical trial program of GR-MD-02, its galectin-3 inhibitor in Nash cirrhosis. Tandem Diabetes Care, Inc. shares closed up 25.22% yesterday but lost some of those gains in after-hours trading.
- Benzinga•last month
Piper Jaffray: Tandem Diabetes Is Entering A 'Goldilocks Period'
Given the FDA's mission to spur innovation and rival Medtronic PLC (NYSE: MDT)’s two-to-three-year delay in 690G, Tandem’s Basal IQ could be approved with DexCom, Inc. (NASDAQ: DXCM)’s G6 in late June, McKim said.
- Motley Fool•last month
Here's Why Tandem Diabetes Care, Inc. Is Rising Today
Shares jump after the company receives some bullish praise from an analyst. Here's what investors need to know.
- Business Wire•last month
Tandem Diabetes Care to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
Tandem Diabetes Care®, Inc. , a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that Kim Blickenstaff, president and CEO, will present a company update at the Bank of America Merrill Lynch 2018 Healthcare Conference, which will be held at the Encore at the Wynn Hotel in Las Vegas, Nevada.
- Business Wire•2 months ago
Tandem Diabetes Care to Present at the Deutsche Bank 43rd Annual Health Care Conference
Tandem Diabetes Care®, Inc. , a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that Kim Blickenstaff, president and CEO, will present a company update at the Deutsche Bank 43rd Annual Health Care Conference in Boston, MA.
- Business Wire•2 months ago
Tandem Diabetes Care Receives CE Mark for t:slim X2 Insulin Pump
The Company plans to begin commercial sales of the pump in select international markets beginning in the second half of 2018. The Company has been commercializing its touchscreen insulin pumps in the United States since 2012, and received U.S. Food and Drug Administration (FDA) approval of the t:slim X2™ Insulin Pump with Dexcom G5 Mobile CGM integration in August 2017.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of TNDM earnings conference call or presentation 26-Apr-18 8:30pm GMT
Q1 2018 Tandem Diabetes Care Inc Earnings Call
- Zacks•2 months ago
Tandem Diabetes Care (TNDM): Moving Average Crossover Alert
Tandem Diabetes Care, Inc. (TNDM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
- Business Wire•2 months ago
Tandem Diabetes Care Announces Agreements for Distribution of Insulin Pump Products in Australia and New Zealand
Tandem Diabetes Care®, Inc. (TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it has entered into distribution agreements with Australasian Medical & Scientific Ltd (AMSL) and New Zealand Medical & Scientific Ltd (NZMS) to commercialize Tandem’s t:slim X2™ Insulin Pump in Australia and New Zealand, respectively.
- Business Wire•2 months ago
Tandem Diabetes Care Schedules First Quarter 2018 Earnings Press Release and Conference Call
Tandem Diabetes Care®, Inc. , a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, plans to release its first quarter 2018 results after the financial markets close on Thursday, April 26, 2018.
- MarketWatch•2 months ago
Harry Boxer’s five biotech stocks to watch
In focus: uniQure, Regenxbio, Tandem Diabetes Care, Vericel and Xencor.
- ACCESSWIRE•2 months ago
Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Tandem Diabetes Care
NEW YORK, NY / ACCESSWIRE / April 11, 2018 / Spectrum Pharmaceuticals and Tandem Diabetes Care both exploded in Tuesday trading. Spectrum headed higher after announcing positive data from a phase 2 trial ...
- Simply Wall St.•2 months ago
Tandem Diabetes Care Inc (NASDAQ:TNDM): Are Analysts Bullish?
Tandem Diabetes Care Inc’s (NASDAQ:TNDM) most recent earnings update in December 2017 suggested company earnings became less negative compared to the previous year’s level as a result of recent tailwindsRead More...
- Motley Fool•2 months ago
Why Tandem Diabetes Care Is Soaring 18.5% Higher Today
A review of its most recent quarter is sparking investor optimism.
- Business Wire•2 months ago
Tandem Diabetes Care Announces Preliminary First Quarter 2018 Results
Tandem Diabetes Care®, Inc. , a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported select, unaudited and preliminary results for the quarter ended March 31, 2018.
- Business Wire•2 months ago
Tandem Diabetes Care and Movi SpA Announce Agreement for Distribution of Insulin Pump Products in Italy
Tandem Diabetes Care®, Inc. , a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that it has entered into a distribution agreement with Movi SpA to commercialize Tandem’s t:slim X2™ Insulin Pump in Italy.
